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Abstract
Preclinical and clinical studies demonstrate the feasibility of treating b-thalassemia and Sickle Cell Disease (SCD) by
lentiviral-mediated transfer of the human b-globin gene. However, previous studies have not addressed whether the
ability of lentiviral vectors to increase hemoglobin synthesis might vary in different patients. We generated lentiviral
vectors carrying the human b-globin gene with and without an ankyrin insulator and compared their ability to induce
hemoglobin synthesis in vitro and in thalassemic mice. We found that insertion of an ankyrin insulator leads to higher,
potentially therapeutic levels of human b-globin through a novel mechanism that links the rate of transcription of the
transgenic b-globin mRNA during erythroid differentiation with polysomal binding and efficient translation, as reported
here for the first time. We also established a preclinical assay to test the ability of this novel vector to synthesize adult
hemoglobin in erythroid precursors and in CD34
+ cells isolated from patients affected by b-thalassemia and SCD. Among
the thalassemic patients, we identified a subset of specimens in which hemoglobin production can be achieved using
fewer copies of the vector integrated than in others. In SCD specimens the treatment with AnkT9W ameliorates
erythropoiesis by increasing adult hemoglobin (Hb A) and concurrently reducing the sickling tetramer (Hb S). Our results
suggest two major findings. First, we discovered that for the purpose of expressing the b-globin gene the ankyrin element
is particularly suitable. Second, our analysis of a large group of specimens from b-thalassemic and SCD patients indicates
that clinical trials could benefit from a simple test to predict the relationship between the number of vector copies
integrated and the total amount of hemoglobin produced in the erythroid cells of prospective patients. This approach
would provide vital information to select the best candidates for these clinical trials, before patients undergo
myeloablation and bone marrow transplant.
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Introduction
b-thalassemia and SCD are two of the most common genetic
red blood cell disorders, affecting millions. Although both
conditions originate from genetic defects that reside within the
b-globin gene, b-thalassemia is characterized by limited or absent
synthesis of b-globin chains [1], whereas SCD by production of an
aberrant b-globin molecule [2].
In b-thalassemia, mutant alleles that are associated with no b-
globin synthesis are classified as b0, while those that allow some
protein synthesis are designated b+. Thalassemic patients are
therefore generally classified as b0/0, +/0 or +/+, based on the
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32345combination of these two alleles [1]. In SCD, the b chain is
mutated at the sixth amino acid, leading to the synthesis of Hb S
instead of normal Hb A [2]. The only definitive cure for both
disorders requires transplantation of allogeneic bone-marrow (BM)
cells, a procedure whose success depends on the availability of
suitable donors and minimal development of graft versus host
disease (GVHD) [3]. Therefore, therapies based on the modifica-
tion of a patient’s own BM cells by adding the corrected b-globin
gene might offer a relatively safe alternative [3,4,5].
Several studies using thalassemic and SCD mouse models
[5,6,7,8,9,10,11,12,13] support the use of lentiviral-mediated
human b-globin gene transfer into autologous hematopoietic stem
cells for the cure of these disorders [14,15,16]. Recently, the first
clinical trial on a patient with Hb E/b-thalassemia was reported
[17]. The success of this first trial was made possible by the
additive effect of transgenic b-globin chains synthesized by the
vector and those (fetal and adult) made by the patient’s cells. Thus,
without the support of endogenous hemoglobins (Hbs), the gene
transfer would not have allowed this patient to become
transfusion-independent. This result suggests that it would be
extremely helpful if one could predict the outcome of gene transfer
before a candidate undergoes myeloablation.
Here we describe a novel lentiviral vector, AnkT9W, that
carries both the human b-globin gene and the erythroid-specific
ankyrin 59 hyper-sensitive (HS) barrier insulator [18]. This vector
is able to maintain high, yet stable levels of Hb synthesis in MEL
cells and in thalassemic mice. Furthermore, using just 30 mL of
blood, we developed a protocol for evaluating the correlation
between the number of AnkT9W-viral integrants (vector copy
number, VCN), and that of b-globin mRNA molecules and the
level of Hb production in peripheral-blood-derived human CD34
+
and erythroid progenitor cells (ErPCs), following in vitro b-globin
gene transfer and erythroid differentiation.
Results
The ankyrin insulator increases hemoglobin synthesis in
murine erythroleukemia (MEL) cells
A lentiviral vector named TNS9 carrying the human b-globin
gene and large elements of the locus control region (LCR)
dramatically reduced anemia in thalassemic mice [6,9,10]. As
previously reported [19], we modified the vector backbone to
increase its safety and efficiency, thereby generating T9W
(Figure 1A).
Insulator elements are known for their (i) enhancer blocking
activity, when placed between an enhancing element and a
promoter [20,21,22,23], and (ii) chromatin barrier activity (i.e,
preventing the spread of heterochromatin into the integrated
transgenic cassette from a nearby heterochromanized chromo-
somal region). The 59 HS ankyrin insulator exhibits only the latter
activity [18], which could prevent susceptibility to transcriptional
silencing [24] and, in turn, increase overall expression. In order to
evaluate whether the ankyrin insulator increases the probability of
transgenic b-globin expression at random chromosomal integra-
tions, we modified T9W by including a copy of this element [18]
(190 bp) in the 39 SIN-LTR, generating AnkT9W. As a control we
generated a vector in which a fragment of DNA (,190 bp) from
the l bacteriophage replaced the ankyrin element (lT9W). We
analyzed pools of MEL cells transduced with T9W, AnkT9W and
lT9W that exhibited comparable VCNs shortly after transduc-
tion. The percentages of chimeric human/mouse Hb over total
Hb (Hb:ma/(mb:ma+Hb:ma)) detected by HPLC was 30.7%,
36.2% and 19.2% in pools of MEL cells infected with T9W,
AnkT9W and lT9W, respectively (Figure 1B). In two pools of
MEL cells with similar copies of T9W and AnkT9W, both the
percentage (Figure 1C) and absolute amount of Hb:ma (Figure 1D)
were higher in those cells carrying the AnkT9W vector. In order to
investigate the cause of increased b–globin synthesis in AnkT9W
transduced cells, we further characterized two pools of MEL cells
carrying three copies of either T9W or AnkT9W, respectively
(Figures 1E–G). We measured the relative amounts of transgenic
human versus endogenous mouse b-globin mRNA expressed over
the course of erythroid differentiation induced by HMBA (N,N9-
hexamethylene-bis acetamide). Quantitative PCR analysis re-
vealed that AnkT9W expressed the transgenic mRNA at a higher
rate than T9W, especially during the early phases of erythroid
differentiation (Figure 1E). In a clinical trial, monitoring the
presence of the integrated vector and the expression of the
transgenic mRNA over time is extremely important for interpret-
ing the outcome of the gene transfer. For this reason, we modified
the b-globin coding sequence with silent mutations that do not
alter the amino acid residues but allow for discrimination between
endogenous and transgenic b-globin DNA and RNA. We
modified several bases in the first and second exons of separate
vectors, generating AnkT9Wsil1 and AnkT9Wsil2 (Table 1 shows
the modified sequences for each vector within exon 1 and 2). As a
first step to compare AnkT9W, T9Wsil1 and AnkT9Wsil2, we
repeated the measurement of the relative amounts of transgenic
human versus endogenous mouse b-globin mRNA during
erythroid differentiation in MEL cells, and observed that both
these vectors increased expression of the transgenic b-globin gene
during erythroid differentiation, as already seen with AnkT9W
(not shown).
Increased b-globin protein with AnkT9W could be a result of
increased translation and/or increased transcription. Polysomal
analysis (Figures 1F–G) indicated that b-globin mRNA transcribed
from AnkT9W co-localized with the polysomal fraction associated
with the highest translational activity (Figure 1G, left). As
expected, there was no difference between the translation
efficiency of endogenous globin (data not shown) and b-actin
mRNAs expressed by either AnkT9W or T9W transduced cells
(Figure 1G, right). Together, these results suggested that the
presence of the ankyrin insulator, irrespective of its localization in
T9W, leads to increased b-globin mRNA and translation
throughout erythropoiesis. These observations indicate that early
expression of the transgenic b-globin messenger may be crucial in
maximizing gene-therapy potential and efficacy in thalassemic
erythroid cells.
The ankyrin element is stably integrated and not subject
to rearrangement in MEL cells carrying a single copy of
the human b-globin transgene
We generated 14 clones of MEL cells carrying single copies of
T9W (N=7) and AnkT9W (N=7), and analyzed their Hb content
at 6 weeks or more and after HMBA-induced differentiation. In
addition, to investigate whether the ankyrin insulator had any
enhancer-blocking activity with respect to b-globin gene expres-
sion, we generated single copy MEL clones (N=6) using a vector,
T9Ank2W, in which this element was inserted between the b-
globin promoter and the LCR (Figure 1A). Four out of 7 clones
bearing T9W synthesized low amounts of human b-globin protein.
In contrast, all the AnkT9W-bearing clones expressed the b-globin
transgene at high levels. On average, the AnkT9W-bearing clones
synthesized 46.6% more Hb:ma (Figure 2A) than the T9W-
bearing ones. The clones bearing the T9Ank2W exhibited
increased b-globin expression, similar to those generated with
AnkT9W. This indicates that the ankyrin element bears no
enhancer blocking activity, but still exerts a positive effect on b-
Advances in Gene Therapy for b-Thalassemia
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e32345Figure 1. Lentiviral constructs and Hb:ma Hb synthesis in MEL cells after lentiviral vectors integration. (A) Black and white rectangles
represent exons and introns, respectively, within the b-globin gene. The human ankyrin insulator (in grey, 190 bp) was introduced into the 39LTR,
thereby generating AnkT9W. In the T9Ank2W vector we inserted the ankyrin element between the HS2 and the b-globin promoter. As a control for
AnkT9W, the lT9W vector was generated, by replacing the ankyrin element with a fragment from the bacteriophage l (190 bp, in white). bp: b-
globin promoter. E
+: b-globin enhancer. LCR: locus control region. HS: DNase I hypersensitive sites. LTR: long terminal repeat. SIN: self-inactivating. (B)
HPLC analyses of murine Hbs (tetramers of two a-chains associated with two b minor/major chains) in control MEL cells, and chimeric human/mouse
Hb (Hb:ma) in MEL cells infected with approximately one copy of T9W (Hb:ma=30.7%), AnkT9W (Hb:ma=36.2%) and lT9W (Hb:ma=19.16%),
respectively. The percentages and absolute amounts of Hb:ma Hb after HMBA differentiation, in pools of MEL cells carrying three copies of T9W or
AnkT9W are shown in C and D, respectively. (E) Expression of human/mouse b-globins expressed over a seven-day differentiation period in MEL cells
carrying 3 copies of either T9W or AnkT9W. Values of both globins are normalized by mouse Gapdh expression. (F) Representative polysomal profile
obtained. Continuous OD254 of 10–50% sucrose gradient with peaks corresponding to the 40 S, 60 S, 80 S and polysomal complexes are indicated.
(G) Analyses of ribosomal RNA expression. Total mRNA of MEL cells carrying approximately 3 copies of T9W or AnkT9W was separated into 13
fractions after sucrose gradient ultra-centrifugation. Polysome-bound RNAs were collected between fractions 10 and 13 and represent messenger
RNA with higher rate of translation. Values of mouse b-actin or human b-globin expression of each fraction were calculated as proportion of the total
RNA.
doi:10.1371/journal.pone.0032345.g001
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promoter and LCR. Tissue-specific expression of the b-globin
transgene was assessed in pro-erythroid (MEL) and non-erythroid
(B-16) cell lines (Figure 2B). Other vectors including insulator
elements have been plagued by low titers or recombination events.
In our hands the ankyrin element did not decrease the viral titer
(comparing T9W vs. AnkT9W). We then investigated if the
integration of the ankyrin insulator in 39 LTR was associated with
recombination events in the two LTRs as well as in the cassette
including the b-globin gene and transcriptional elements. To this
end, we verified that each ankyrin insulator sequence was stably
integrated in both the 39 and 59 LTR of 7 MEL clones bearing a
single copy of AnkT9W. Using specific primers that discriminate
between the ankyrin sequence in the 39 or 59 LTR, we observed
that each clone amplified two sequences of the expected size
(Figure 2C). In addition, Southern blot analysis indicated that all
Table 1. Sequences of exon 1 and 2 in AnkT9W and AnkT9Wsil1/2 silent mutants.
Canonic exon 1 (inside AnkT9W):
ATGGTGCACCTGACTCCTGAGGAGAAGTCTGCCGTTACTGCCCTGTGGGGCAAGGTGAACGTGGATGAAGTTGGTGGTGAGGCCCTGGGCAG
Silent mutant exon 1 (inside AnkT9Wsil1):
ATGGTGCACCTGACTCCTGAGGAGAAGTCTGCCGTTACTGCCCTGTGGGGCAAGGTGAACGTGGATGAAGTCGGCGGCGAGGCCCTGGGCAG
Canonic exon 2 (inside AnkT9W):
GCTGCTGGTGGTCTACCCTTGGACCCAGAGGTTCTTTGAGTCCTTTGGGGATCTGTCCACTCCTGATGCTGTTATGGGCAACCCTAAGGTGAAGGCTCATGGCAAGAAAGTGCTCGGTG-
CCTTTAGTGATGGCCTGGCTCACCTGGACAACCTCAAGGGCACCTTTGCCACACTGAGTGAGCTGCACTGTGACAAGCTGCACGTGGATCCTGAGAACTTCAGG
Silent mutant exon 2 (inside AnkT9Wsil2):
GCTGCTGGTGGTCTACCCTTGGACCCAGAGGTTCTTTGAGTCCTTTGGGGATCTGTCCACTCCTGATGCTGTTATGGGCAACCCTAAGGTGAAGGCTCATGGCAAGAAAGTGCTCGGTG-
CCTTCTCCGATGGCCTGGCTCACCTGGACAACCTCAAGGGCACCTTTGCCACACTGAGTGAGCTGCACTGTGACAAGCTGCACGTGGATCCTGAGAACTTCAGG
Original and corresponding mutated bases of exons 1 and 2 inside constructs are in bold letters.
doi:10.1371/journal.pone.0032345.t001
Figure 2. The ankyrin insulator improves translation of the b-globin gene, and its sequence is conserved at the site of integration.
(A) Expression of the chimeric Hb (expressed as a percentage) after HMBA differentiation, in MEL cell clones carrying one VCN of T9W or AnkT9W, and
T9Ank2W. One way anova test, p=0.048. (B) The b-globin mRNA (bottom panel), expressed by T9W (VCN=0.87,1.4), AnkT9W (VCN=0.39, 1.07, 1.47)
and T9Ank2W (VCN=1.26, 1.98) was not detected in non-erythroid cells (B-16 melanoma) but only in differentiated MEL cells (AnkT9W, VCN=2),
indicating that the transgene’s transcription is tissue specific. (C) Two amplicons were amplified by PCR corresponding to the ankyrin sequence
present, respectively, in the 59 and 39 viral LTRs. Oligonucleotides were designed to include the ankyrin element and selectively amplify fragments
either from the 59 or 39 LTR. Only clones bearing a single AnkT9W integrant were used. The amplified fragments exhibited the expected size of
248 bp and 231 bp, indicating that the ankyrin element was faithfully replicated in both LTRs. (D) Southern blot assay of genomic DNA from single
integrant clones of MEL cells carrying either T9W or AnkT9W or from MEL control. The genomic DNAs were digested with XmnI restriction enzyme,
which yielded the full b-globin cassette, identified by hybridization using a b-globin BamHI-NcoI probe. Clone #6 of the AnkT9W series was reloaded
in higher quantity (left panel) to amplify the signal of the transgenic human b-globin gene, because it was insufficiently loaded and exhibited a weak
signal on the first blot (right panel).
doi:10.1371/journal.pone.0032345.g002
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a 6.2 kb fragment, including the b-globin gene and all the
transcriptional elements (Figure 2D).
The vector carrying the ankyrin element improves
correction of the phenotype of thalassemic mice
To compare the ability of the T9W and AnkT9W vectors to
produce Hb in vivo, we engrafted mice affected by thalassemia
intermedia (Hbb
th3/+) [25,26] with Hbb
th3/+ BM cells transduced
with either T9W or AnkT9W. Figures 3A, B show the absolute
Hb:ma and the total Hb (Hb:ma together with endogenous mouse
Hb) content reached at 3 months and later in Hbb
th3/+ mice
engrafted with either T9W- or AnkT9W-treated Hbb
th3/+ BM
cells, respectively.
Compared to mice transplanted with un-manipulated Hbb
th3/+
BM, the chimeric and total hemoglobin contents were increased
and red cell counts were significantly improved in all chimeras
carrying AnkT9W. Compared to Hbb
th3/+ controls, the increases
in average Hb values were 1.7 and 3.4 g/dL for T9W-Hbb
th3/+
and AnkT9W-Hbb
th3/+ mice, respectively. The ability of AnkT9W
to increase Hb synthesis was supported by the observation that
these parameters were corrected at relative low VCNs (0.960.3
Figure 3. AnkT9W improves Hb synthesis and hematological parameters of thalassemic mice. Red cell hemolysates were analyzed
monthly by HPLC for up to 6 months post BM transplant. Chimeric (A) and total absolute Hb content (B) in T9W-Hbb
th3/+ and AnkT9W-Hbb
th3/+
chimeras (n=4 and 6, respectively). Hb:ma Hb detected by HPLC and relative VCN (C and D) in mice chimeras obtained by transplanting Hbb
th3+ BM
treated with T9W or AnkT9W vectors into lethally irradiated Hbb
th3+ recipient mice. (E, F) Hematologic parameters in WT, Hbb
th3/+, T9W-Hbb
th3/+ or
AnkT9W-Hbb
th3/+ chimeras. On average, the hematocrits in AnkT9W-treated chimeras were 26% and 10% higher, the reticulocyte counts 71% and
49% lower, and the RDWs 35% and 22% lower than in Hbb
th3/+ and T9W-Hbb
th3/+ mice, respectively. For reticulocyte counts, Hb, RDW, p,0.0001,and
for HCT, p=0.0002.
doi:10.1371/journal.pone.0032345.g003
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th3/+ and T9W-Hbb
th3/+
chimeras, respectively; Figures 3C, D). The hematocrit, reticulo-
cyte count and red cell distribution width (RDW) in AnkT9W-
Hbb
th3/+ chimeras were nearly identical to those of mice engrafted
with normal bone marrow (Figures 3E, F). Both T9W-Hbb
th3/+
and AnkT9W-Hbb
th3/+ chimeras exhibited a lower percentage and
absolute number of immature erythroid cells (CD71
+/Ter119
+)
than mature ones (CD71
2/Ter119
+, Figure 4A) and significantly
reduced splenomegaly (Figure 4B), compared to Hbb
th3/+ untreat-
ed chimeras. Compared to Hbb
th3/+ and T9W-Hbb
th3/+ chimeras,
AnkT9W-Hbb
th3/+ chimeras showed a more remarkable correction
of their RBC morphology (microcytosis, hypochromia and
poikilocytosis; Figure 4C, left panel), while organ morphology in
the liver (Figure 4C, middle panel) and spleen (Figure 4C, right
panel) were similarly corrected.
Long-term expression of chimeric hemoglobin is
sustained in secondary and tertiary chimeras
transplanted with AnkT9W-treated Hbb
th3/+ bone marrow
To assess long-term synthesis of b-globin in thalassemic
hematopoietic cells transduced with AnkT9W, we collected the
bone marrow of a primary chimera and transplanted it into an
Hbb
th3/+ recipient and then repeated the process so as to establish a
tertiary chimera. In the latter mice, we measured the level of
chimeric hemoglobin (using both HPLC and cellulose acetate
electrophoresis essays), hematological indices, the iron content of
the liver and spleen (Figures 5A–C), and the proportion of
immature/mature erythroid cells in the spleen (data not shown).
The expression of chimeric hemoglobin in both secondary and
tertiary chimeras was comparable to that of the primary chimera
as were all other parameters, confirming that a sustained
correction of the phenotype can be achieved utilizing AnkT9W.
Amelioration of the phenotype in thalassemic human
ErPCs treated with AnkT9W
Since AnkT9W showed an increased ability to express the
transgenic b-globin gene in MEL cells and a more efficient long-
term correction of the thalassemic phenotype in mice, we chose
AnkT9W to study the correlation between viral integration and
phenotypic correction of human thalassemic cells. In patients with
b-thalassemia, the amount of b-globin synthesis is the major
determinant of phenotype. ErPCs were isolated from peripheral
blood and then expanded and differentiated via a modified version
of the two-phase liquid culture system [27]. Compared to controls,
the percentages of Hb A (a2: b2 tetramer) were 53% in b+/+ cells
(N=8), 17% in b+/0 cells (N=6), and almost undetectable in b0/
0 cells (N=5) (not shown). Moreover, we eluted and characterized
(via mass spectrometry) a peak observed in the HPLC profiles of
thalassemic patients and positioned between those of the Hb Fs
and Hb A. This analysis indicated that this peak corresponded to
a-globin aggregates. This peak was not detected in any of the
healthy control or carrier samples. The average amounts of a-
globin aggregates were 965% in b+/+ cells, 865% in b0/+ cells,
and 23614% in b0/0 cells. The corresponding amounts of Hb F
varied from 22611% in b+/+ cells, to 54623% in b0/+ cells, and
53618% in b0/0 cells. The list of all patients analyzed in this
study and their mutations is reported in Tables 2 and 3.
We then determined the optimal conditions for infecting the
cells with AnkT9W so as to achieve a VCN between 0.1 and 2,
which is the expected range of transduction in a clinical setting.
Using the same approach we also tested the ability of AnkT9Wsil2
to increase the levels of adult hemoglobin in a small subset of
patient ErPCs, showing that the silent mutation did not alter the
ability of the transgenic mRNA to generate adult hemoglobin
(Figure 6B, ErPCs samples transduced by AnkT9Wsil2 are
indicated by the ‘‘*’’ sign). The variation of Hb A content after
treatment versus the number of integrations is shown in Figure 6A.
Following transduction of ErPCs from b0/0 patients (on left,
N=5), we observed an increase in Hb A proportional to the VCN
(ranging from 0.1 to approximately 1.0; with more than 95% of
the cells hemoglobinized as indicated by benzidine staining). In
Figure 6B the total percentage of Hb A is shown before and after
treatment. Concomitantly, the percentages of fetal hemoglobins
(Figure 6C) and a-globin aggregates (Figure 6D) were dramatically
reduced. Representative HPLC profiles of untreated (left) and
AnkT9W-treated (right) b0/0 and b+/+ samples are shown in
Figures 7A and B, respectively.
Interestingly, although the VCNs in transduced b0/+ (N=6)
and b+/+ cells (N=8) were similar to those in b0/0 cells, the net
percentage increases of Hb A were less dramatic. In fact, up to a
VCN equal to one, linear regression analysis revealed that b0/0
cells exhibited a higher response relative to the number of
integrations (r squared=0.47, p=0.017), than b0/+ cells (r
squared=0.11, p=0.35) or b+/+ cells (r squared=0.12,
p=0.047). On the other hand, the total Hb A% in both b0/+
and b+/+ cells, which takes into account both endogenous and
lentiviral-induced Hb, was higher than in b0/0 cells after
transduction as shown in Figure 8A. This suggests that it might
be possible to reach therapeutic levels of Hb A% in both b+/+ and
b0/+ cells at low VCN. Furthermore, we observed that the total
Hb A% reached a plateau in many patient specimens at relatively
low VCNs. For these reasons, we narrowed down our analysis to
samples exhibiting VCNs equal to or less than 0.6. Using this
arbitrary threshold, the total amount of Hb A synthesized in b0/+
and b+/+ cells after transduction was comparable (54%623%
and 68%67%, respectively) to that measured in carrier cells
(80%63%) and significantly higher (p,0.0001) than that
produced by b0/0 cells (36%616%) (Figure 8B). On the other
hand, our analysis indicates that AnkT9W reaches complete
therapeutic levels only in b0/0 specimens exhibiting the highest
VCNs. Altogether, these observations suggest that b0/+ and b+/+
patients are more likely to achieve therapeutic levels of Hb A than
b0/0 patients at integration levels that reduce genotoxicity risk
and myeloablation regimens in a clinical setting. We also
measured the absolute Hb A content at baseline and after
treatment in the three groups of thalassemic cells, as well as in
healthy controls and carrier cells. After treatment with AnkT9W,
the average absolute amount of HbA in 1610
6 erythroid cells was
increased in all groups, rising from 0 to 2.9761.91 mgi nb0/0,
from 0.2460.16 mg to 2.3762.29 mgi nb0/+ and from
2.7261.47 mg to 5.0361.92 mgi nb+/+ cells. In order to correlate
the absolute increase of Hb A after treatment with the VCN, we
focused on b0/0 cells, which do not express any endogenous Hb
A. The amount of Hb A produced by AnkT9W-treated b0/0 cells
(normalized to 1 VCN) corresponded to 76% of that synthesized
by carrier ErPCs (Figure 8C). This suggests that in this group one
copy of AnkT9W might not be sufficient to raise Hb A to the levels
necessary to achieve transfusion independence.
CD34
+ cells isolated from the peripheral blood of
thalassemic patients express high levels of Hb A after
treatment with AnkT9W
In order to maximize our pre-clinical approach, we developed a
method to expand, differentiate and treat CD34
+ cells in vitro
following isolation from the blood via selective immunomagnetic
separation. We used a modified version of the expansion system
described by Leberbauer and colleagues [28]. This method has the
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CD34
+ cells that can be variously manipulated (i.e. frozen, thawed,
infected, and analyzed for viral integration). Erythroid develop-
ment was monitored using CD44 [29], Band3 and glycophorin A
(CD235a) surface markers (Figures 8 D–G). Our results show that
undifferentiated cells express high levels of the CD44 marker and
Figure 4. Hematopoietic parameters, splenomegaly and EMH of AnkT9-treated Hbb
th3/+- are comparable to those of WT-chimeras.
(A) Flow cytometry. CD71/Ter119 antibodies (y/x axes, respectively) were utilized to assess the correction of ineffective erythropoiesis in
representative WT and Hbb
th3/+ mice and in Hbb
th3/+ mice treated with T9W or AnkT9W lentiviral vectors, in spleen (top) and bone marrow (bottom).
(B) Mice spleen size. (C) From top to bottom: a WT mouse transplanted with WT bone marrow; an Hbb
th3/+ that received Hbb
th3/+ bone marrow
untreated or transduced with T9W or AnkT9W. Liver and spleen morphology of the same animals are shown in the middle and right panels,
respectively. (C, left panel) Blood smears stained with May-Grunwald-Giemsa staining, showing the RBCs morphology of representative mice. Sections
of liver and spleen were also analyzed to assess extramedullary hematopoiesis (EMH) and organ morphology. The livers from both T9W- and AnkT9W-
treated chimeras were similar to those of normal control mice in which no EMH was detected (C, middle panel). In the spleens of Hbb
th3/+ mice, the
cross-sectional area of the white pulp (C, right panel) was relatively decreased and the marginal zones were obscured by the large number of
nucleated RBCs, reflecting major expansion of the red pulp and erythroid precursors. In mice treated with T9W, and even more so in AnkT9W-treated
chimeras, the amount of red pulp was decreased considerably, accounting for only about 40% to 50% of the cross-sectional area, and denoting a
considerable reduction of EMH.
doi:10.1371/journal.pone.0032345.g004
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2/CD235a
2. As differentiation progressed, both
control and thalassemic cells gradually became Band3
+ and
CD235a
+, while the mean fluorescence of the CD44 marker
regressed, as previously observed by Chen and colleagues [29] in
the erythroid maturation of BM-derived murine CD34
+ cells. The
profiles of untreated and treated thalassemic cells did not differ
throughout differentiation, although Hb A synthesis improved
dramatically (from 0% to 62%, with a VCN=0.92, as shown in
Figure 9A and B).
CD34
+ cells derived from SCD patients and treated with
AnkT9W Increased expression of Hb A to therapeutic
levels
Gene therapy using lentiviral vectors encoding a normal b-
globin gene may also provide a definitive cure for patients affected
by SCD. However, one limitation of this approach is due to the
fact that the b-globin encoded by the vector must replace the
mutant b-globin chain in the adult hemoglobin tetramer made by
the patient’s red cells, without increasing the total amount of b-
globin protein produced. We next investigated whether AnkT9W
could increase the synthesis of Hb A without increasing the total
amount of Hbs synthesized in SCD cells.
As expected, CD34-derived erythroid cells of SCD patients do
not synthesize Hb A. A representative example of the Hb synthesis
pattern of an untreated SCD sample is shown in Figure 10A (left)
and compared to the same sample treated with AnkT9W (right).
At baseline 8 SCD samples synthesized on average 26.54%64.5%
of Hb F and 73.46%64.5% of Hb S, while Hb A was not
detected. After treatment with AnkT9W both Hb F and S were
significantly reduced (to 19.83%66.36%, p=0.001 and to
49.66613.91, p,0.0001, respectively). On average, Hb A from
undetected increased to 30.48%617.89%, with a mean VCN of
0.9860.86. The changes in Hb A, F and S% in all 8 samples
before and after treatment are shown in Figure 10B from top to
Figure 5. Long-term expression of Hb:ma Hb and correction of the phenotype in thalassemic mice. (A) Hematological parameters, spleen
size, and iron content in primary, secondary and tertiary chimeras. (B) HPLC profiles of Hbb
th3+ control mouse (upper left quadrant) compared to
primary (right upper quadrant), secondary (left lower quadrant) and tertiary (right lower quadrant) BMT chimeras transplanted with AnkT9W-treated
BM cells. (C) Cellulose acetate of primary (top) and secondary (bottom) BMT chimeras.
doi:10.1371/journal.pone.0032345.g005
Advances in Gene Therapy for b-Thalassemia
PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e32345bottom, respectively. After treatment with AnkT9W, there was a
significant correlation between HbA increase and VCN
(p,0.0001, r
2=0.56, Figure 10C), while absolute total Hb
content, measured by extrapolation of peak areas, did not change
(Figure 10D), indicating that the quality rather than the quantity of
Hb determined the phenotypic correction in these cells.
Discussion
Based on encouraging results in mice [6,7,8,10,11,12,13] and
driven by the urgent need for a definitive cure for thalassemia and
SCD, a clinical trial was initiated in 2007 [17] using a lentiviral
vector that expresses a modified adult b-globin gene (b
A(T87Q)),
flanked by two copies of the 250-base-pair core of the cHS4
chromatin insulator [30] implanted in the U3 region. After gene
transfer, the patient became transfusion independent. However,
the therapeutic Hb-b
A(T87Q) in this patient contributed only one-
third of the total Hb synthesized, while Hb E and Hb F accounted
equally for the remaining Hb. In addition, about two-thirds of the
viral integrations examined contained a deletion of one of the
cHS4 cores within the 39-LTR and the remaining one-third
presented a deletion of a cHS4 core within the 59-LTR.
Furthermore, erythroid cells from this patient exhibited a
dominant, myeloid-biased cell clone, in which the integrated
vector caused transcriptional activation of HMGA2. HMGA2
upregulation can lead to a clonal growth advantage [31]. The
integrated vector introduced a cryptic 39 splice signal within the
cHS4 insulator core and cleavage/polyadenylation within the
adjacent R region of the 39-LTR that triggered alternative splicing
of HGMA2. This alternative spliced form lacked a distal portion of
the HGMA2 transcript containing multiple binding sites for let-7
microRNAs, which normally controls HGMA2 degradation [31].
Duplication of the cHS4 core element triggers recombination,
deletion of at least one of the two elements and consequent loss of
insulating activity that, in concert with the disruption of the full-
length HGMA2 transcript, likely leads to HGMA2 upregulation. An
additional question is whether upregulation of HMGA2 plays any
role in the increased HbF observed in this patient post bone
marrow transplant. Therefore, the complications associated with
the cHS4 element and upregulation of HMGA2 suggest that an in
vitro test, such as the one proposed in our study, could have
addressed this question. A thorough analysis of CD34-derived
cells, infected with serial dilutions of the vector utilized in this trial,
could have indicated the predisposition of the cHS4 to recombine
and could have quantified the HbF level prior to bone marrow
transplant. Nevertheless it is undeniable that this approach has
great potential for success, as evidenced by the fact that this patient
no longer needs transfusion therapy, does not manifest any
malignant or pre-malignant state and has significantly improved
quality of life.
The number and complexity of the mutations within the
thalassemic population is a source of great phenotypic variability.
This raises concern that some patients, based on their genetic
profiles and endogenous hemoglobin production, might be better
candidates for transplant than others. This is especially important
in light of the intrinsic ability of the specific vectors used in the
different clinical trials to make hemoglobin. To date, no study has
focused on the correlation between gene transfer and increased
hemoglobin levels in patients carrying different b-globin mutations
and exhibiting wide phenotypic variability.
To address this important issue we generated a lentiviral vector
expressing the human b-globin gene and bearing the ankyrin
Table 2. Mutations in patients.
Group Patient ID Mutations
b0/0 (A) 1A Nt168/Nt168
2A Codon6/Nt168
3A, 5A IVS-I-1/IVS-I-1
4A IVS-II-1/Nt 168
b0/+ (B) 1B, 2B, 3B IVS-I-110/Nt168
4B IVS-I-5/Codon 15
5B IVS-II-654/Codon71–72
6B IVS-I-I/IVS-II-745
b+/+ (C) 1C IVS-I-6/IVSI-110
2C, 3C, 5C IVS-I-110/IVSI-110
4C, 6C IVS-I-6/IVSII-745
7C IVS-I-6/Nt-30
8C IVS-II-745/IVS-II-745
List of b-thalassemia specimens analyzed in this study.
doi:10.1371/journal.pone.0032345.t002
Table 3. Mutations phenotype.
b Type Mutation ID Category of defect
b0 Nt168/b039 (CRT) Nonsense Mutation producing nonfunctional mRNA
Codon 71–72 (+A) Frame-shift Mutation producing nonfunctional RNA
IVS-I-1 (GRA) Splice site junction mutation
IVS-II-1 (GRA) Splice site junction mutation
Codon 15 (TGGRTGA) Nonsense Mutation producing nonfunctional mRNA
b+ IVS-I-5 (GRT) Processing mutant-Mutation at the splicing consensus site
IVS-I-6 (TRC) Processing mutant-Mutation at the splicing consensus site
IVS-I-110 (GRA) Mutations Creating Alternative Splice Sites
IVS-II-654 (CRT) Mutations Creating Alternative Splice Sites
IVS-II-745 (CRG) Mutations Creating Alternative Splice Sites
230 (TRA) Promoter Mutations-ATA Box
Description of b0a n db+ mutations.
doi:10.1371/journal.pone.0032345.t003
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tested this vector in vitro and in thalassemic mice. In particular, in
MEL cells we discovered that gene the ankyrin element is greatly
suitable for the purpose of expressing the b-globin. In fact, when
associated to the b-globin gene, the ankyrin insulator not only
increases its transcription rate but also induces expression at an
earlier stage of differentiation in erythroid cells. Furthermore, a
higher b-globin mRNA level associated with translationally active
ribosomes in cells transduced with AnkT9W, compared to those
transduced with T9W, ultimately leads to greater translation of the
transgene. In other words, our study suggests that the ability of the
various b-globin lentiviral vectors to compensate for the lack of b-
globin chain is not only dependent on the relative rate of
transcription of the transgenic cassette, but also on its temporal
activation during erythroid differentiation. In addition, AnkT9W
showed significantly less variability of b-globin synthesis in MEL
cell clones containing a single integrated copy, compared to T9W.
As previously reported [18], our results confirm that the ankyrin
insulator does not have enhancer-blocking activity. Indeed, we did
not observe any reduction in b-globin synthesis in differentiated
MEL clones that were transduced with a single copy of T9Ank2W,
which carries an ankyrin insulator between the b-globin promoter
Figure 6. AnkT9W increases HbA synthesis to therapeutic levels in most of the thalassemic ErPCs. (A) Net increase of Hb A % (DHb A,
calculated by subtracting Hb A after treatment from that following treatment) is plotted against VCN (on the X axis) in the three patients groups, b0/
0, b0/+ and b+/+. The total Hb A% is also represented as percentage of Hb A before (light grey) and after transduction (dark grey) with AnkT9W in the
same groups (B). Figures C and D show the concomitant percentages of Hb F and a-aggregates, both of which are reduced in thalassemic ErPCs after
treatment with AnkT9W. The tie bars under the X axes group different specimens from the same individual. Several specimens were harvested and
transduced at different times so as to expose the variability in such experiments. ‘‘*’’ Sign indicates specimens treated with AnkT9Wsil2.
doi:10.1371/journal.pone.0032345.g006
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of chimeric Hb compared to T9W, similar to what we measured in
cells tranduced with AnkT9W. Therefore, we speculate that an
additional ankyrin cassette could be placed between these two
elements to maximize b-globin expression, and that an additional
insulator/enhancer-blocking element could be introduced into the
39SIN-LTR. Novel and shorter elements derived from the cHS4
that confer enhancer-blocking activity do not require duplication
in order to be effective, and do not decrease the viral titer.
Therefore, they could be utilized for this purpose [32].
Furthermore, we observed that this vector was also effective in
mice affected by b-thalassemia intermedia when administered via
BMT of HSCs pretreated with the lentiviral construct, producing
a phenotype more similar to that of WT mice transplanted with
normal BM.
Our study was then designed to identify an in vitro protocol
which could predict correction of both the thalassemic and SCD
phenotype in a large pool of patient samples. In this regard, we
discovered that AnkT9W increased the synthesis of b-globin
protein in most thalassemic and SCD specimens to levels
comparable to those observed in carriers and control samples.
However, after treatment a subset of thalassemic samples, mostly
b0/0, exhibited the lowest amount of total HbA (transgenic and
endogenous). In other words, b0/0 specimens required higher
amounts of vector to reach therapeutic levels of Hb, whereas b0/+
and b+/+ benefitted from the expression of the endogenous HbA
and reached curative levels at lower VCNs. Furthermore,
irrespective to the b-globin mutations, additional mechanisms,
potentially associated with genetic modifiers and/or other
unknown factors, may contribute to the variability observed
following gene transfer. For this reason, some b0/0 patients and
patients that do not exhibit an increase in HbA proportional to the
VCN should be carefully investigated to determine if they would
be good candidates for a clinical trial based on this approach. To
our knowledge, this is the first study that clearly correlates the
genotype, the endogenous levels of hemoglobins and the vector
copy number with the phenotypic outcome. Because these findings
are clinically relevant, we believe that future clinical trials should
take these factors under careful considerations before treating
patients. Furthermore, we found that in SCD specimens the
treatment with AnkT9W can correct the phenotype by modifying
the proportion of sickling versus functional Hb, without changing
the overall Hb content.
In general, we believe that analysis of erythroid progenitors
transduced with different amounts of lentiviral vectors could be
useful for testing the potential of each lentiviral construct prior to
BMT.
In summary, our results suggest that clinical trials could benefit
from a simple test to predict the relationship between the number
of vector copies integrated and the total amount of hemoglobin
produced using the erythroid cells of prospective patients. The
data presented herein support the use of a simple pre-clinical test
to determine the potential efficacy of a given gene therapy
treatment in patient-derived cells prior to myeloablation and
transplant.
Materials and Methods
Human and Animal Ethics
All study participants were enrolled through written consent,
according to protocol #05070077971, approved by the Weill
Cornell Medical College Institutional Review Board. The periferal
blood samples from the SCD patients were obtained during
automated red cell exchange as part of their routine clinical care at
Figure 7. HPLC profiles of thalassemic specimens analyzed after differentiation from ErPCs-derived cultures. HPLC profiles from b0/0
(A) and b+/+ thalassemic ErPCs (B) at steady state (left), and after treatment (right) with AnkT9W. F, A, A2 (a2d2) Hbs and a-aggregates are indicated by
arrows.
doi:10.1371/journal.pone.0032345.g007
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deidentified medical waste, the Montefiore Medical Center
Institutional Review Board deemed them to be IRB exempt.
Experiments conducted on mice were approved by the Weill
Cornell Medical College Institutional Animal Care and Use
Committee, as described in the protocol #0601-436A.
Figure 8. AnkT9W increases Hb A synthesis in thalassemic specimens derived from CD34
+ cells, maintaining erythropoietic
development unaltered. Figure A shows the percentage of total Hb A versus the number of AnkT9W integrations in the three major specimen
groups. In figure B the Hb A% in ErPCs of thalassemic patients measured at baseline and after treatment with AnkT9W (VCN up to 0.6 copies) is
compared to those of carriers and controls. In figure C the absolute Hb A content of 1610
6 erythroid cells in the carrier, control and b0/0 groups
(normalized to the VCN) is indicated. Flow cytometry analysis of Band3/CD44 expression in normal (D) or thalassemic (E) CD34 cells from steady state
and throughout erythroid differentiation. The expression of the two markers was analyzed on day 2-4-7 and 9 in b0/0 thalassemic cells untreated (F)
or transduced with 0.92 copies of AnkT9W (G). The profiles did not differ throughout differentiation in the two experimental conditions, although
HbA synthesis improved dramatically (see Figure 9).
doi:10.1371/journal.pone.0032345.g008
Advances in Gene Therapy for b-Thalassemia
PLoS ONE | www.plosone.org 12 March 2012 | Volume 7 | Issue 3 | e32345Vector production and titration
Viral stocks were generated by co-transfection of the gene
transfer plasmid (i.e. T9W, AnkT9W) together with the
envelope plasmid (VSV-G), the packaging plasmid (pMDLg/p
RRE), and the pRSV-REV vector into 293T cells [6,33]. An
aliquot (5610
6)o f2 9 3 Tc e l l sw a ss e e d e di n t oc e l lc u l t u r ed i s h e s
(10 cm) 24 hours prior to transfection in Iscove’s modification of
Eagle’s medium (DMEM, Cellgro, Manassas, VA) with 10%
fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml
streptomycin, at 37uCu n d e r5 %C O 2. The culture medium
was changed 2 hours prior to transfection. The precipitate was
formed by adding the plasmids to 450 uL of 0.16TE (0.16TE
is 10 mM Tris plus 1 mM EDTA) and 50 mLo f2MC a C l 2,
then adding 500 mLo f2 6 HEPES-buffered saline (281 mM
NaCl, 100 mM HEPES, 1.5 mM Na2HPO4)d r o p w i s ea f t e r
which the precipitate was vortexed and immediately added to
the cultures. The medium (10 ml) was replaced after 16 hours.
Viral supernatants were collected at 24 and 48 hours, cleared by
low speed centrifugation, and filtered through cellulose acetate
(0.2 mm). Following concentration by ultracentrifugation, serial
dilutions of concentrated virus (5; 0.5 and 0.05 mL, respectively)
were used to infect 1610
5 NIH 3T3 cells (ATCC, Manassas,
VA) in 1 mL of transfection buffer complemented with
polybrene (Millipore, Billerica, MA) at a final concentration of
8 mg/mL. Genomic DNA was extracted after 3 days (Qiagen
kit, Valencia, CA). The multiplicity of infection (MOI) was
calculated using the following formula: number of cells
(1610
5)6dilution factor (1 mL/mL viral preparation) X VCN
(measured via real-time PCR, using oligos for WPRE element
and ID gene, see below).
MEL cell culture and differentiation
Murine erythroleukemia cells [34] were grown in DMEM
(Cellgro), supplemented with 10% FBS (Hyclone, South Logan,
UT) and 1% penicillin/streptomycin. Erythroid differentiation
was achieved by seeding 2610
6 cells, in log phase, into 3 mL of
fresh culture media containing HMBA, at a final concentration of
1 mg/mL. Treatment with HMBA was repeated after 2 and 4
days of culture, cells being collected for analysis after 6 days and
every day for time-course analysis.
Southern blot analysis
For identification of viral genomic stability genomic DNA from
MEL cells was isolated, digested with XmnI, and investigated by
Southern blot analysis using a [
32P]dCTP-labeled NcoI/BamHI
probe from the human b-globin gene. Since this fragment shares
more than 90% homology with the mouse b-globin gene, both the
human (top) and mouse (bottom) b-globin gene hybridized to this
probe.
Generation of bone marrow transplanted chimeras
Murine bone marrow cells were harvested from WT and
Hbb
th3/+ donor mice (Jackson Laboratories, Bar Harbor, ME).
Bone marrow cells were resuspended in X-VIVO-15 serum-free
medium and supplemented with 10 ng/mL IL-1a, 100 U/mL IL-
3, 150 U/mL IL-6, 10 ng/mL Kit ligand obtained from Genzyme
(Cambridge, MA), 0.5 mM b-mercaptoethanol obtained from
Sigma (St Louis, MO), 200 mM L-glutamine, 100 IU/mL
penicillin, and 100 mg/mL streptomycin. Cells were then pelleted
and resuspended in serum-free medium containing concentrated
lentiviral supernatant, supplemented with 4 mg/mL polybrene
obtained from Sigma, 200 mM L-glutamine, 100 U/mL penicil-
lin, 100 mg/mL streptomycin, and cytokines as above, and
cultured for 8 hours. Transduced and control cells (2610
6) were
then intravenously injected into each of the irradiated female
recipients to establish bone marrow chimeras. Recipient mice (8-
to 10-week-old C57/BL6 mice) were irradiated with 12 Gy (split
dose 266 Gy) on the day of transplantation.
Figure 9. HPLC profiles of thalassemic specimens analyzed after differentiation from CD34-derived cultures. The HPLC profiles of the
same thalassemic b0/0 (A) and b+/+ (B) specimens were analyzed at steady state (left) and following treatment with AnkT9W (right) after
differentiation starting from either CD34
+ cells (top) or ErPCs (bottom). In the same b0/0 specimen, AnkT9W contributes to increasing Hb A synthesis
from from 0% to 62% (VCN=0.92), in the CD34
+-derived cells or to 73% (VCN=0.97), in the ErPCs-derived cells. In the cells from the b+/+ patient, the
net Hb increase was 35% (VCN=0.88), if CD34
+-derived or 23% (VCN=0.94), if ErPCs-derived.
doi:10.1371/journal.pone.0032345.g009
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Insertion of the ankyrin insulator at both viral LTRs was
confirmed by PCR using two sets of oligonucleotides annealing
within the ankyrininsulator and a region of the viral genome present
exclusively at the 59 or the 39 sites. To amplify the ankyrin in the 59
LTR weutilized the following oligonucleotides:ankyrin/LTR59-FW
59-TGCCCCGGATGTAGGCATGCG-39, and LTR59-REV 59-
CGCCATGCTAGAGATTTTCCACA-39, which anneals within
the viral sequence in the primer binding site. To amplify the ankyrin
inthe 39 LTR we utilized the following oligonucleotides:LTR39-FW
59-ACTGGAAGGGCTAATTCACTCCCA-39 which anneals
within the NEF viral sequence, and Ankyirin/LTR39-REV 59-
AGGTGCTCTTGTAATCTGCGGT.
Retrotranscription of total mRNA was done using the Super-
Script
TM II First Strand Kit (Invitrogen, Carlsbad, CA). Q-PCR
reactions were performed using the ABI Prism 7700 Sequence
Detection System (Applied Biosystems, Foster City, CA), with
either TaqMan (TaqMan PCR 26 Master mix; Applied
Biosystems) or SYBR Green (iTaqTM SYBRH Green Supermix,
Bio-Rad Laboratories, Hercules, CA) chemistry. Quantitative real-
time PCR assays of globin transcripts were carried out using gene-
specific double fluorescently labeled probes. The following primer
and probe sequences were used (forward, reverse and probe of
each gene, respectively): b: Fw: 59-CAAGAAAGTGCTC-
GGTGCCT-39; Rev: 59- GCAAAGGTGCCCTTGAGGT-39;
59-FAM-TAGTGATGGCCTGGCTCACCTGGAC-TAMRA-
39; a: Fw: 59-TCCCCACCACCAAGACCTAC-39; Rev: 59-CC-
TTAACCTGGGCAGAGCC-39;5 9-FAM-TCCCGCACTTCG-
ACCTGAGCCA-TAMRA-39. For real-time PCR of the refer-
ence genes, we used as an endogenous control the human
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) kit, in
which the probe is fluorescently labeled with VIC (Applied
Biosystems). The number of integrations (VCN) was quantified by
Q-PCR using oligos (Fw: 59-CGGCTGTTGGGCACTGA-39;
Rev: 59-GGAAGGTCCGCTGGATTGA-39) and a probe (59-
FAM-ATGGCTGCTCGCCTGTGTTGCC-TAMRA-39) for a
specific sequence present in the vector (WPRE) and compared it to
an endogenous control present in two copies within the genome
Figure 10. AnkT9W increases Hb A synthesis in SCD specimens derived from CD34
+ cells, maintaining total hemoglobin content
unaltered. (A) HPLC profile of a SCD specimen at steady state (left) or after treatment with AnkT9W (right). (B) Hb A% increase (top) and
concomitant Hb F% (middle) and Hb S% (bottom) decrease after treatment with AnkT9W. (C) Increase of Hb A% is plotted against VCN. The tie bars
under the X axes group different specimens from the same individual. Several specimens were harvested and transduced at different times so as to
expose the variability in such experiments. (D) Total Hb content before and after treatment with AnkT9W, obtained measuring the areas under
hemoglobin peaks detected by HPLC.
doi:10.1371/journal.pone.0032345.g010
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TTCCGAGTTCAGCTCCAACTG-39).
Two-phase liquid cultures, benzidine staining and
transduction
Consented patients with b-thalassemia major, b-thalassemia
carriers and healthy individuals donated between 20 and 30 mL of
peripheral blood. To isolate ErPCs or CD34
+ cells, we first
separated the mononuclear fraction by Ficoll-Hypaque density
gradient. We selectively expanded ErPCs by seeding them into a-
modified essential medium (a-MEM) containing 10% fetal calf
serum (Biological Industries, Beit-Haemek, Israel), streptomycin
(100 U/mL), glutamine (100 mg/mL), stem cell factor (10 ng/
mL) and (1 mg/mL) cyclosporine A (Sigma, St. Louis, MO).
Alternatively, we selected CD34
+ cells by immunomagnetic
separation, using the CD34 microbeads kit (Miltenyi Biotec Inc.,
Auburn, CA) and then expanded these cells following a modified
version of the protocol described by Leberbauer and colleagues.
Cells were seeded in 5 mL of serum-free StemSpan with 50 mLo f
StemSpan CC-100 cytokine cocktail (both from Stemcell Tech-
nologies, Vancouver, BA, Canada), 2 U/mL Erytrhopoietin
(Amgen, Thousand Oaks, CA), 10
26 M dexamethasone (Sigma)
and 1% penicillin streptomycin. CD34
+ cultures were kept
undifferentiated by refreshing the medium twice a week and
density gradient centrifugation was used to remove both dead and
spontaneously differentiating cells. At day 10, cells were analyzed
by flow cytometry showing a homogenous population character-
ized as being C-kit
+, CD34
+, CD235a
2 and Band3
2 (not shown).
At this stage cells were either frozen (with 50% chracterized
Hyclone FBS, 10%DMSO, Sigma, and 40% Iscove’s Modified
DMEM, Cellgro), or used for experiments. After 5 to 7 days (for
the ErPCs) or 3 weeks (for the CD34
+ cells) in phase I, cells were
transferred into phase II media containing a-modified essential
medium supplemented with 30% fetal calf serum and 10
25 M b-
mercaptoethanol. Erythropoietin was added (10 U/mL) to
stimulate erythroid differentiation. Cells were infected with serial
dilutions of the viruses, starting with MOI 0.3 and multiples of it.
Cells were collected on day 10 of phase II for all analyses. The
level of differentiation was assessed by benzidine staining. Briefly,
1 mL of a solution made by adding 1 g of benzidine dihydro-
chloride to 14.6 mL of glacial acetic acid was mixed with 20 mL of
33% H2O2. Cells were mixed (at a 1:1 ratio) with the activated
benzidine and immediately scored for blue staining in a
hemotocytometer.
High performance liquid chromatography (HPLC)
Cell pellets were lysed with HPLC-grade water and loaded into
a System Gold 126 Solvent Module instrument (Beckman Coulter,
Fullerton, CA). Hbs were separated on a cation-exchange
Synchropak CM300 column (Eichrom Technologies, Inc, Darien,
IL), and detected at a wavelength of 415 nm. The Hbs were
bound to the column with mobile phase B (10 mmol/L Bis-Tris,
1 mmol/L KCN, pH 6.3) and eluted with mobile phase A
(10 mmoI/L Bis-Tris, 1 mmol/L KCN containing sodium acetate
trihydrate, pH 6.15). Serial dilutions of a solution with known
concentrations of Hb A and Hb F (Analytical Control System, Inc,
Fishers, IN) were used to generate a calibration curve, where the
absorbance detected at 415 nm was plotted against the concen-
tration values. Types and quantity of Hbs in samples were assessed
by comparison to standard hemoglobin controls.
Polysomal analysis
Polysome fractions were isolated on sucrose gradients. The
amount of mRNA in each fraction was determined to evaluate the
association between the ribosomes and endogenous or transgenic
b-globin mRNAs. Cells were homogenized in lysis buffer (100 mM
NaCl, 10 mM MgCl2, 30 mM Tris-HCl, pH 7.5, 1 mM DTT,
30 U/ml RNasin) supplemented with 1% Triton X-100. After
incubation on ice for 5 minutes, the lysates were centrifuged at
4uC for 10 minutes at 12,0006g. The supernatants were then
loaded on a 10%–50% (w/v) sucrose gradient and sedimented by
centrifugation at 34,000 rpm for 180 min using a Beckman SW41
rotor. Each gradient was separated into 13 fractions. RNA was
extracted from each fraction and analyzed by RT-PCR.
Statistical analyses
For two-group comparisons we used either paired or unpaired t-
tests (where normal distributions and equal variances were met) or
Mann Whitney and Wilcoxon tests. For comparison of three or
more groups, we computed means with a one-way Anova test (for
samples with normal distributions and equal variances) or medians
with a non-parametric Kruskal-Wallis test. Correlation between
variables was evaluated by linear regression. All tests were done
using GraphPad Prism software, version 5.0a.
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